The Food and Drug Administration has approved two new HIV treatments containing the active ingredient lenacapavir, available in both injectable and tablet form. The drugs are designed for adult patients with multidrug-resistant HIV-1 infections who have exhausted existing antiretroviral therapies and have no other viable treatment options.
HIV targets CD4+ T cells, a key component of the immune system, progressively weakening the body’s defenses and potentially advancing to AIDS if left untreated. The newly approved medications work as selective inhibitors targeting HIV-1’s capsid protein, which protects the virus’s genetic material and replication enzymes. The drugs suppress HIV-1 replication by blocking the virus’s entry into cell nuclei, disrupting viral assembly and release, and triggering abnormal capsid formation.
The FDA fast-tracked approval by designating the treatments as the 46th product under its Global Innovative Product Fast Track Review System, aimed at accelerating availability in clinical settings. An FDA spokesperson noted that the treatments are expected to address unmet medical needs that current therapies have been unable to meet. The agency reaffirmed its commitment to using advanced regulatory science to deliver safe and effective treatments for rare and hard-to-treat conditions.
